Coherus BioSciences (CHRS) Tops Q3 EPS by 15c
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.30 --0%
Revenue Growth %: +37.8%
Financial Fact:
Selling, general, and administrative expenses: 137.78M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Revenue Growth %: +37.8%
Financial Fact:
Selling, general, and administrative expenses: 137.78M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q3 EPS of ($0.01), $0.15 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $70.77 million versus the consensus estimate of $58.98 million.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- B. Riley previews Semi Cap Equipment sector ahead of Semicon West
- Domino's Pizza (DPZ) PT Lowered to $325 at Guggenheim
- Compass Therapeutics (CMPX) PT Lowered to $4 at Guggenheim
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
